Catalent, Inc. (NYSE: CTLT), the leader in enabling the
development and supply of better treatments for patients worldwide,
today announced the appointment of Sridhar Krishnan, to the newly
created position of Vice President, The Catalent Way, where he will
lead the company’s operational excellence strategy and spearhead a
transformation based on Lean principles, designed to drive
sustainable execution excellence, enabling growth. He will also
serve on the Executive Leadership Team, reporting directly to
Catalent’s President & Chief Executive Officer, Alessandro
Maselli.
This press release features multimedia. View
the full release here:
https://www.businesswire.com/news/home/20230306005036/en/
Sridhar Krishnan, who joins Catalent as
Vice President, "The Catalent Way", which is a company-wide
transformation based on Lean principles and designed to drive
sustainable execution excellence. (Photo: Business Wire)
The Catalent Way is a company-wide system of continuous
improvement with clear standards to enable more predictable and
efficient processes. Mr. Krishnan will work alongside senior
executives across the company’s business segments, and more than 50
global facilities, to implement this strategy.
Mr. Krishnan returns to Catalent having spent the previous four
years in a number of roles within the pharmaceutical industry, most
recently as SVP, Head of Operations, for Jubilant Pharma. He has
over 20 years of operational leadership experience within the CDMO
space, including as Vice President of Global Operations, and
subsequently as Vice President, Global Procurement & Business
Analytics at Catalent. He holds a bachelor’s degree in mechanical
engineering and is a Six Sigma Master Black Belt.
Commenting on the appointment, Alessandro Maselli said, “Sridhar
brings considerable operational leadership and Lean expertise, as
well as a proven track record driving enterprise-wide business
transformations and operational performance. We welcome him back to
Catalent, in a role where he will provide the key strategic focus
necessary to not only establish new standards of excellence at
Catalent, but within the pharmaceutical industry.”
Notes for Editors
About Catalent, Inc.
Catalent, Inc. (NYSE: CTLT), an S&P 500® company, is the
global leader in enabling pharma, biotech, and consumer health
partners to optimize product development, launch, and full
life-cycle supply for patients around the world.
With broad and deep scale and expertise in development sciences,
delivery technologies, and multi-modality manufacturing, Catalent
is a preferred industry partner for personalized medicines,
consumer health brand extensions, and blockbuster drugs. Catalent
helps accelerate over 1,000 partner programs and launch over 150
new products every year. Its flexible manufacturing platforms at
over 50 global sites supply around 80 billion doses of nearly 8,000
products annually.
Catalent’s expert workforce of approximately 18,000 includes
more than 3,000 scientists and technicians. Headquartered in
Somerset, New Jersey, the company generated nearly $5 billion in
revenue in its 2022 fiscal year. For more information
www.catalent.com.
More products. Better treatments. Reliably supplied.™
Forward Looking Statements
This release contains both historical and forward-looking
statements. All statements other than statements of historical
fact, are, or may be deemed to be, forward-looking statements
within the meaning of Section 27A of the Securities Act of 1933, as
amended, and Section 21E of the Securities Exchange Act of 1934, as
amended. These forward-looking statements generally can be
identified by the use of statements that include phrases such as
“believe,” “expect,” “anticipate,” “intend,” “estimate,” “plan,”
“project,” “predict,” “hope,” “foresee,” “likely,” “may,” “could,”
“target,” “will,” “would,” or other words or phrases with similar
meanings. Similarly, statements that describe Catalent’s
objectives, plans, or goals are, or may be, forward-looking
statements. These statements are based on current expectations of
future events. If underlying assumptions prove inaccurate or
unknown risks or uncertainties materialize, actual results could
vary materially from Catalent’s expectations and projections. Some
of the factors that could cause actual results to differ include,
but are not limited to, the following: the current or future
effects of the COVID-19 pandemic or any global health developments
on Catalent's or its customers' or suppliers' businesses;
participation in a highly competitive market and increased
competition that may adversely affect Catalent’s business; demand
for its offerings, which depends in part on its customers’ research
and development and the clinical and market success of their
products; product and other liability risks that could adversely
affect Catalent’s results of operations, financial condition,
liquidity and cash flows; failure to comply with existing and
future regulatory requirements; failure to provide quality
offerings to customers could have an adverse effect on Catalent’s
business and subject it to regulatory actions and costly
litigation; problems providing the highly exacting and complex
services or support required; global economic, political and
regulatory risks to Catalent’s operations, including risks from
rising inflation, disruptions to global supply chains, or from the
Ukrainian-Russian war; inability to enhance existing or introduce
new technology or service offerings in a timely manner; inadequate
patents, copyrights, trademarks and other forms of intellectual
property protections; fluctuations in the costs, availability, and
suitability of the components of the products Catalent
manufactures, including active pharmaceutical ingredients,
excipients, purchased components and raw materials; changes in
market access or healthcare reimbursement in the United States or
internationally; fluctuations in the exchange rate of the U.S.
dollar against other currencies; adverse tax legislative or
regulatory initiatives or challenges or adjustments to Catalent’s
tax positions; loss of key personnel; risks generally associated
with information systems; inability to complete any future
acquisition or other transaction that may complement or expand its
business or divest of non-strategic businesses or assets and
difficulties in successfully integrating acquired businesses and
realizing anticipated benefits of such acquisitions; risks
associated with timely and successfully completing, and correctly
anticipating the future demand predicted for, capital expansion
projects at existing facilities; offerings and customers’ products
that may infringe on the intellectual property rights of third
parties; environmental, health, and safety laws and regulations,
which could increase costs and restrict operations; labor and
employment laws and regulations or labor difficulties, which could
increase costs or result in operational disruptions; additional
cash contributions required to fund Catalent’s existing pension
plans; substantial leverage that may limit its ability to raise
additional capital to fund operations and react to changes in the
economy or in the industry; and exposure to interest-rate risk to
the extent of its variable-rate debt preventing it from meeting its
obligations under its indebtedness. For a more detailed discussion
of these and other factors, see the information under the caption
“Risk Factors” in Catalent’s Annual Report on Form 10-K for the
fiscal year ended June 30, 2022, filed August 29, 2022. All
forward-looking statements speak only as of the date of this
release or as of the date they are made, and Catalent does not
undertake to update any forward-looking statement as a result of
new information or future events or developments except to the
extent required by law.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20230306005036/en/
Media Chris Halling +44 (0) 7580 041073
chris.halling@catalent.com Investors Paul Surdez +1 (732)537
6325 investors@catalent.com
Catalent (NYSE:CTLT)
Historical Stock Chart
Von Jun 2024 bis Jul 2024
Catalent (NYSE:CTLT)
Historical Stock Chart
Von Jul 2023 bis Jul 2024